Personality traits, interpersonal problems and therapeutic alliance in early schizophrenia spectrum disorders.

Ragnhild Johansen,I. Melle,V. Iversen,K. Hestad

DOI: https://doi.org/10.1016/j.comppsych.2013.05.016

IF: 7.211

2013-11-01

Comprehensive Psychiatry

Abstract:

What problem does this paper attempt to address?

Non-infectious Chronic Uveitis in Childhood: Assessment and Treatment in the Biological Era

Roberta Ponti,Maria Vincenza Mastrolia,Gabriele Simonini

DOI: https://doi.org/10.1007/s40674-020-00166-7

2021-01-06

Current Treatment Options in Rheumatology

Abstract:Purpose of reviewReport of currently available treatment strategies for childhood chronic uveitis in the biologic era.Recent findingsThe management of non-infectious chronic uveitis in children is based on immunomodulatory treatment. In case of failure to conventional disease-modifying anti-rheumatic drugs (cDMARDs) and/or frequent flares, tumor necrosis factor alfa (TNF-α) blocking agents represent the first biologic choice. Adalimumab is the TNF-α inhibitor more frequently adopted. Two multicenter, double-blind, randomized, placebo-controlled trials stated its efficacy and safety in this clinical setting.For refractory diseases, not responsive to TNF-α inhibitors, emerging biologic therapies have been reported. Most of the current literature refers to expert opinion and remains non-standardized. However, retrospective studies and short-case series report tocilizumab, abatacept, and rituximab as promising biologic alternatives in patients with refractory, sight-threatening uveitis even in children. A window of opportunity is currently emerging for JAK inhibitors.SummaryThe role of anti-TNF-α inhibitor in chronic uveitis therapy met unanimous level of agreement. Rescue therapy approach still remains controversial. Randomized controlled trials and large series with long-term follow-up are mandatory to assess efficacy, safety, and cost-effectiveness in this challenging disease.
Biological Therapy of Traditional Therapy-Resistant Adult-Onset Still’s Disease: an Evidence-Based Review

Sha Zhou,Jianjun Qiao,Juan Bai,Yinhua Wu,Hong Fang

DOI: https://doi.org/10.2147/tcrm.s155488

2018-01-01

Therapeutics and Clinical Risk Management

Abstract:Background Biotherapy is becoming increasingly important in the treatment of adult-onset Still’s disease (AOSD). The aim of our study was to evaluate the efficacy and safety of biological therapy for AOSD resistant to traditional therapy. Patients and methods Database of Library of Congress, the PubMed, and Web of Science Core Collection were used to retrieve relevant articles published in English language until March 2017. Only studies published in English language were included, and the additional references quoted in these articles were also checked. Articles concerning the efficacy and safety of all the biotherapies in refractory AOSD were evaluated. Results There were 112 articles available in total; 422 AOSD patients were given at least one biologic. We found that 293 patients (69.43%) had received TNF-α blocking agents (infiliximab, etanercept, and adalimumab), 194 patients (45.97%) were treated with IL-1 receptor antagonists (anakinra, rilonacept, and canakinumab), 163 patients (38.63%) were given IL-6 inhibitor (tocilizumab), and 24 patients (5.69%) received rituximab and abatacept. The efficacy of biological therapy and overall tolerance of biological therapy for refractory AOSD were good. Thirty two of 271 patients given anti-TNF-α therapies (11.81%), 116 patients receiving IL-1 inhibitors (65.54%), 124 patients receiving tocilizumab (76.07%), and 13 patients given other biological therapies (36.11%) achieved remission. Side effects of biologic therapy were infections such as urinary tract infections and soft tissue abscess. Conclusion Our findings suggest that anakinra and tocilizumab may be good choices for the treatment of refractory AOSD considering the effectiveness and safety.
An Update on Treatment of Pediatric Chronic Non-infectious Uveitis

Arjun B. Sood,Sheila T. Angeles-Han

DOI: https://doi.org/10.1007/s40674-017-0057-z

2017-01-26

Current Treatment Options in Rheumatology

Abstract:Opinion statementThere are no standardized treatment protocols for pediatric non-infectious uveitis. Topical corticosteroids are the typical first-line agent, although systemic corticosteroids are used in intermediate, posterior, and panuveitic uveitis. Corticosteroids are not considered to be long-term therapy due to potential ocular and systemic side effects. In children with severe and/or refractory uveitis, timely management with higher dose disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents is important. Increased doses earlier in the disease course may lead to improved disease control and better visual outcomes. In general, methotrexate is the usual first-line steroid-sparing agent and given as a subcutaneous weekly injection at >0.5 mg/kg/dose or 10–15 mg/m2 due to better bioavailability. Other DMARDs, for instance mycophenolate, azathioprine, and cyclosporine, are less common treatments for pediatric uveitis. Anti-tumor necrosis factor-alpha agents, primarily infliximab and adalimumab, are used as second-line agents in children refractory to methotrexate or as first-line treatment in those with severe complicated disease at presentation. Infliximab may be given at a minimum of 7.5 mg/kg/dose every 4 weeks after loading doses, and up to 20 mg/kg/dose. Adalimumab may be given up to 20 or 40 mg weekly. In children who fail anti-tumor necrosis factor-alpha agents, develop anti-tumor necrosis factor-alpha antibodies, experience adverse effects, or have difficulty with tolerance, there is less data available regarding subsequent treatment. Promising results have been noted with tocilizumab infusions every 2–4 weeks, abatacept monthly infusions, and rituximab.
Religious Involvement and Health in Dialysis Patients in Saudi Arabia

F. Al Zaben,D. Khalifa,M. Sehlo,S. Al Shohaib,S. Binzaqr,A. Badreg,Rawan Alsaadi,H. Koenig

DOI: https://doi.org/10.1007/s10943-014-9962-8

2015-04-01

Journal of Religion and Health

Abstract:
Electrochemical genosensor assay using lyophilized gold nanoparticles/latex microsphere label for detection of Vibrio cholerae.

P. S. Liew,B. Lertanantawong,Su Yin Lee,Ravichandran Manickam,Yook Heng Lee,W. Surareungchai

DOI: https://doi.org/10.1016/j.talanta.2015.02.054

2015-07-01

Abstract:
Isolated bilateral abducent nerve palsy in infectious mononucleosis.

Sukanta Nandi,A. Biswas

DOI: https://doi.org/10.1007/S13312-014-0422-Z

2014-06-01

Indian Pediatrics

Abstract:
A Summary of the Latest Data from a 5-Year Literature Review (2018–2023)

Monika Modrzejewska,Oliwia Zdanowska

DOI: https://doi.org/10.3390/jcm13113097

IF: 3.9

2024-05-26

Journal of Clinical Medicine

Abstract:Pediatric uveitis has a low incidence. It is very diverse in its presentation and is often the first sign of a severe systemic disease. The pediatric population poses a special therapeutic and diagnostic challenge due to the potentially adverse effects of therapeutic agents on the young body and difficult cooperation with the patient during the examination, as well as the increased risk of complications that can lead to severe disability. The most commonly diagnosed type of uveitis is non-infectious, with first-line therapy consisting of systemic corticosteroids followed by disease-modifying drugs (methotrexate (MTX), mycophenolate mofetil (MMF), and cyclosporin A (CsA)). In severe, refractory cases, biologic therapy is used. The authors reviewed the current literature on the etiology, diagnostic tools, and treatment of uveitis in the pediatric population covering the years 2018–2023, presenting current methods of modern diagnosis and treatment. The reason for writing this article was the need to update the knowledge on uveitis, driven by the increasing prevalence of autoimmune uveitis in the pediatric population. This trend presents significant challenges in diagnosing and treating the disease, as well as managing its complications. Correctly identifying the pathogenetic factor of uveitis can facilitate the diagnosis of the systemic disease underlying the ocular infection and enable the timely implementation of systemic treatment. Furthermore, the emergence of new diagnostic methods necessitates a revision and update of ophthalmic knowledge, essential for both ophthalmologists and other specialists involved in the treatment of uveitis.

medicine, general & internal
NOD-Like Receptor P3 Inflammasome Controls Protective Th1/Th17 Immunity against Pulmonary Paracoccidioidomycosis

C. Feriotti,E. F. de Araújo,F. V. Loures,T. A. da Costa,N. A. L. Galdino,D. Zamboni,V. Calich

DOI: https://doi.org/10.3389/fimmu.2017.00786

IF: 7.3

2017-07-10

Frontiers in Immunology

Abstract:The NOD-like receptor P3 (NLRP3) inflammasome is an intracellular multimeric complex that triggers the activation of inflammatory caspases and the maturation of IL-1β and IL-18, important cytokines for the innate immune response against pathogens. The functional NLRP3 inflammasome complex consists of NLRP3, the adaptor protein apoptosis-associated speck-like protein, and caspase-1. Various molecular mechanisms were associated with NLRP3 activation including the presence of extracellular ATP, recognized by the cell surface P2X7 receptor (P2X7R). Several pattern recognition receptors on innate immune cells recognize Paracoccidioides brasiliensis components resulting in diverse responses that influence adaptive immunity and disease outcome. However, the role of NLRP3 inflammasome was scantily investigated in pulmonary paracoccidioidomycosis (PCM), leading us to use an intratracheal (i.t.) model of infection to study the influence of this receptor in anti-fungal immunity and severity of infection. For in vivo studies, C57BL/6 mice deficient for several NLRP3 inflammasome components (Nlrp3−/−, Casp1/11−/−, Asc−/−) as well as deficient for ATP receptor (P2x7r−/−) were infected via i.t. with P. brasiliensis and several parameters of immunity and disease severity analyzed at the acute and chronic periods of infection. Pulmonary PCM was more severe in Nlrp3−/−, Casp1/11−/−, Asc−/−, and P2x7r−/− mice as demonstrated by the increased fungal burdens, mortality rates and tissue pathology developed. The more severe disease developed by NLRP3, ASC, and Caspase-1/11 deficient mice was associated with decreased production of IL-1β and IL-18 and reduced inflammatory reactions mediated by PMN leukocytes and activated CD4+ and CD8+ T cells. The decreased T cell immunity was concomitant with increased expansion of CD4+CD25+Foxp3 regulatory T (Treg) cells. Characterization of intracellular cytokines showed a persistent reduction of CD4+ and CD8+ T cells expressing IFN-γ and IL-17 whereas those producing IL-4 and TGF-β appeared in increased frequencies. Histopathological studies showed that all deficient mouse strains developed more severe lesions containing elevated numbers of budding yeast cells resulting in increased mortality rates. Altogether, these findings led us to conclude that the activation of the NLRP3 inflammasome has a crucial role in the immunoprotection against pulmonary PCM by promoting the expansion of Th1/Th17 immunity and reducing the suppressive control mediated by Treg cells.
Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond

Khushboo Chauhan,Mudit Tyagi

DOI: https://doi.org/10.3389/fopht.2024.1412930

2024-08-02

Frontiers in Ophthalmology

Abstract:Non-infectious uveitis (NIU) encompasses a range of conditions marked by inflammation within various layers of the eye. NIU is a significant contributor to irreversible vision loss among the working-age population in developed countries. The aim of treating uveitis is to manage inflammation, prevent its recurrences and to restore or salvage vision. Presently, the standard treatment protocol for NIU involves initiating corticosteroids as the primary therapeutic agents, although more aggressive approaches and steroid sparing agent may be necessary in certain cases. These advanced treatments option include synthetic immunosuppressants like antimetabolites, calcineurin inhibitors and alkylating agents. For patients who exhibit an intolerance or resistance to corticosteroids and conventional immunosuppressive therapies, biologic agents have emerged as a promising alternative. Notably, among the biologic treatments evaluated, TNF-α inhibitors, anti-CD20 therapy and alkylating agents have shown considerable efficacy. In this review, we delve into the latest evidence surrounding the effectiveness of biologic therapy and introduce novel therapeutic strategies targeting immune components as potential avenues for advancing treatment of NIU.

Medicine
Pediatric uveitis: A comprehensive review

Arash Maleki,Stephen D Anesi,Sydney Look-Why,Ambika Manhapra,C Stephen Foster

DOI: https://doi.org/10.1016/j.survophthal.2021.06.006

Abstract:Pediatric uveitis accounts for 5-10% of all uveitis. Uveitis in children differs from adult uveitis in that it is commonly asymptomatic and can become chronic and cause damage to ocular structures. The diagnosis might be delayed for multiple reasons, including the preverbal age and difficulties in examining young children. Pediatric uveitis may be infectious or noninfectious in etiology. The etiology of noninfectious uveitis is presumed to be autoimmune or autoinflammatory. The most common causes of uveitis in this age group are idiopathic and juvenile idiopathic arthritis-associated uveitis. The stepladder approach for the treatment of pediatric uveitis is based on expert opinion and algorithms proposed by multidisciplinary panels. Uveitis morbidities in pediatric patients include cataract, glaucoma, and amblyopia. Pediatric patients with uveitis should be frequently examined until remission is achieved. Once in remission, the interval between follow-up visits can be extended; however, it is recommended that even after remission the child should be seen every 8-12 weeks depending on the history of uveitis and the medications used. Close follow up is also necessary as uveitis can flare up during immunomodulatory therapy. It is crucial to measure the impact of uveitis, its treatment, and its complications on the child and the child's family. Visual acuity can be considered as an acceptable criterion for assessing visual function. Additionally, the number of cells in the anterior chamber can be a measure of disease activity. We review different aspects of pediatric uveitis. We discuss the mechanisms of noninfectious uveitis, including autoimmune and autoinflammatory etiologies, and the risks of developing uveitis in children with systemic rheumatologic diseases. We address the risk factors for developing morbidities, the Standardization of Uveitis Nomenclature (SUN) criteria for timing and anatomical classifications, and describe a stepladder approach in the treatment of pediatric uveitis based on expert opinion and algorithms proposed by multi-disciplinary panels. In this review article, We describe the most common entities for each type of anatomical classification and complications of uveitis for the pediatric population. Additionally, we address monitoring of children with uveitis and evaluation of Quality of Life.
The present status of canine parvovirosis.

R. H. Johnson,I. A. Mc Candlish,J. Wilson

DOI: https://doi.org/10.1080/01652176.1983.9693877

Veterinary Quarterly

Abstract:Results from studies performed by the authors and by other workers, have greatly increased the knowledge of canine parvovirus. The authors review the situation with particular reference to virology, epidemiology, pathogenesis, pathology and immunoprophylaxis.
New therapies in development for the management of non‐infectious uveitis: A review

Muhammad Hassan,Samendra Karkhur,Jeong H. Bae,Muhammad S. Halim,Maria S. Ormaechea,Neil Onghanseng,Nam V. Nguyen,Rubbia Afridi,Yasir J. Sepah,Diana V.,Quan D. Nguyen,Diana V. Do

DOI: https://doi.org/10.1111/ceo.13511

2019-04-01

Clinical and Experimental Ophthalmology

Abstract:Uveitis is a spectrum of inflammatory disorders characterised by ocular inflammation and is one of the leading causes of preventable visual loss. The main aim of the treatment of uveitis is to control the inflammation, prevent recurrences of the disease, and preserve vision while minimizing the adverse effects associated with the therapeutic agents. Initial management of uveitis relies heavily on the use of corticosteroids. However, monotherapy with hi‐dose corticosteroids is associated with side effects and cannot be maintained long term. Therefore, steroid‐sparing agents are needed to decrease the burden of steroid therapy. Currently, the therapeutic approach for non‐infectious uveitis (NIU) consists of a step‐ladder strategy with the first line option being corticosteroids in various formulations followed by the use of first, second, and third line agents in cases with suboptimal steroid response. Unfortunately, the agents currently at our disposal have limitations such as having a narrow therapeutic window along with their own individual potential side‐effect profiles. Therefore, research has been targeted to identify newer drugs as well as new uses for older drugs that target specific pathways in the inflammatory response. Such efforts are made in order to provide targeted and safer therapy with reduced side effects and greater efficacy. Several specially designed molecular antibodies are currently in various phases of investigations that can potentially halt the inflammation in patients with NIU. In the review, we have provided a comprehensive overview of the current and upcoming therapeutic options for patients with NIU.

ophthalmology
To switch or to swap? Evidence from a meta-analysis for the best treatment approach in childhood chronic uveitis resistant to the I anti-TNF

Ilaria Maccora,Sara Soldovieri,Teodoro Oliverio,Salvatore de Masi,Edoardo Marrani,Ilaria Pagnini,Maria Vincenza Mastrolia,Gabriele Simonini

DOI: https://doi.org/10.1016/j.jtauto.2024.100247

2024-06-22

Abstract:Objective: Since adalimumab approval in childhood chronic non-infectious uveitis (cNIU), the prognosis has been dramatically changed, but the 25 % failed to achieve inactivity. There is not accordance if it is better to switch to another anti-TNF or to swap to another category of biologic. Thus, we aim to summarize evidence regarding the best treatment of cNIU refractory to the first anti-TNF. Methods: A systematic literature review and meta-analysis, according to PRISMA Guidelines, was performed(Jan2000-Aug2023). Studies investigating the efficacy of treatment in cNIU refractory to the first anti-TNF were considered for inclusion. The primary outcome was the improvement of intraocular inflammation according to SUN. A combined estimation of the proportion of children responding to switch or swap and for each drug was performed. Results: 23 articles were eligible, reporting 150 children of whom 109 switched anti-TNF (45 adalimumab, 49 infliximab, 9 golimumab) and 41 swapped to another biologics (31 abatacept, 8 tocilizumab and 1 rituximab). The proportion of responding children was 46 %(95 % CI 23-70) for switch and 38 %(95 % CI 8-73) for swap (χ20.02, p = 0.86). Instead analysing for each drug, the proportion of responding children was the 24 %(95 % CI 2-55) for adalimumab, 43 %(95 % CI 2-80) for abatacept, 79 %(95 % CI 61-93) for infliximab, 56 %(95 % CI 14-95) for golimumab and 96 %(95 % CI 58-100) for tocilizumab. We evaluated a superiority of tocilizumab and infliximab compared to the other drugs(χ2 27.5 p < 0.0001). Conclusion: Although non-conclusive, this meta-analysis suggests that, after the first anti-TNF failure, tocilizumab and infliximab are the best available treatment for the management of cNIU.
Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry

Maria Tarsia,Antonio Vitale,Carla Gaggiano,Jurgen Sota,Anna Maselli,Chiara Bellantonio,Silvana Guerriero,Rosanna Dammacco,Francesco La Torre,Gaafar Ragab,Mohamed Tharwat Hegazy,Alex Fonollosa,Maria Pia Paroli,Emanuela Del Giudice,Maria Cristina Maggio,Marco Cattalini,Lampros Fotis,Giovanni Conti,Angela Mauro,Adele Civino,Federico Diomeda,Alejandra de-la-Torre,Carlos Cifuentes-González,Samar Tharwat,José Hernández-Rodríguez,Verónica Gómez-Caverzaschi,Laura Pelegrín,Kalpana Babu,Vishali Gupta,Francesca Minoia,Piero Ruscitti,Stefania Costi,Luciana Breda,Saverio La Bella,Alessandro Conforti,Maria Antonietta Mazzei,Ester Carreño,Rana Hussein Amin,Salvatore Grosso,Bruno Frediani,Gian Marco Tosi,Alberto Balistreri,Luca Cantarini,Claudia Fabiani

DOI: https://doi.org/10.1007/s40123-023-00863-1

2024-01-13

Ophthalmology and Therapy

Abstract:Since many biological drug patents have expired, biosimilar agents (BIOs) have been developed; however, there are still some reservations in their use, especially in childhood. The aim of the current study is to evaluate the efficacy and safety of tumor necrosis factor (TNF) inhibitors BIOs as treatment for pediatric non-infectious uveitis (NIU).

ophthalmology
Use of immunomodulators in non-infectious uveitis: lights and shadows

Carolina Bernal-Morales,Athimalaipet V. Ramanan,Carlos Pavesio

DOI: https://doi.org/10.1038/s41433-024-03294-9

IF: 4.4563

2024-08-21

Eye

Abstract:Non-infectious uveitis (NIU) is one of the leading causes of sight impairment worldwide. Corticosteroids are the mainstay treatment for acute NIU, although their known systemic and ocular side effects limit their long-term use. The most common types of immunosuppressants used as steroid-sparing treatment are non-biologic drugs, particularly antimetabolites (methotrexate, mycophenolate mofetil, and azathioprine) and biologic drugs, mainly TNF-α inhibitors such as Adalimumab or Infliximab. Antimetabolites have shown their effectiveness in the treatment of NIU in individual and comparative studies, being methotrexate and mycophenolate mofetil usually preferred over azathioprine. The choice of which antimetabolite to use at first is not well defined, and decisions usually depend on the patient's characteristics and the physician's preferences. Treatment of NIU with biologic drugs, and particularly TNF-α inhibitors, has significantly increased in the last years and is considered an important alternative in patients not responding to first-line immunomodulators such as antimetabolites. However, data regarding how different immunomodulators or biologic drugs perform in different NIU is still limited, and little is known about the optimization of both biologic and non-biologic drugs when used in NIU. Further randomized clinical trials and comparative studies are required to achieve more understanding and better results when addressing complicated NIU. The purpose of this review is to provide a comprehensive overview of the use of non-biologic and biologic drugs in NIU, which may be useful for clinicians in their daily practice, and to address those aspects that are less known about these treatments as well as their weaknesses.

ophthalmology
[Research Update of Anti-Tnf-α Biologic Agents in the Treatment of Uveitis].

Fan,Min Zhou,Yi Luo

DOI: https://doi.org/10.3760/cma.j.issn.0412-4081.2013.03.022

2013-01-01

Abstract:Uveitis is one of the common sight-threatening eye diseases, which is usually recurrent and refractory to treatment. It is generally considered that the development of uveitis is closely related to the autoimmune response of uvea. Tumor necrosis factor (TNF)-α is one of the key cytokines involved in the emergence and progression of uveitis. Blocking the production or inhibiting the activity of TNF-α can inhibit the development or progression of uveitis. Presently, the commercially available TNF-α blockers include infliximab, adalimumab, etanercept, and golimumab. This review describes the clinical studies and adverse effects of TNF-α blockers in the treatment of uveitis, and discusses the principle for clinical use of TNF-α blockers in synergy with other immunosuppressive agents.
Efficacy of adalimumab in noninfectious pediatric uveitis: Analysis of 29 eyes from a tertiary eye care center in India

Nida Khan,Parthopratim Dutta Majumder,Mahesh Janarthanan,Jyotirmay Biswas

DOI: https://doi.org/10.4103/IJO.IJO_3223_23

2024-07-11

Abstract:Purpose: To describe the treatment outcomes of adalimumab in noninfectious pediatric uveitis. Methods: The electronic medical records of children with noninfectious uveitis were reviewed retrospectively. The visual improvement and ocular inflammation were assessed according to the Standardization of Uveitis Nomenclature criteria before and after treatment with adalimumab. Results: Twenty-nine eyes of 16 patients were included. The mean age of children was 9.4 ± 3.8 years. There were eight (50%) males and eight (50%) females. Juvenile idiopathic arthritis was the most common cause of uveitis in these children (N = 10, 62.5%), followed by Behçet's disease (N = 3, 18.75%) and Vogt-Koyanagi-Harada disease (N = 2, 12.5%). One child (6.25%) was diagnosed with Crohn's disease. Nine (56.3%) children were previously treated with methotrexate, one each with mycophenolate mofetil (MMF) (6.3%), azathioprine (6.3%), and tofacitinib (6.3%), and one child received MMF followed by azathioprine and cyclosporine before shifting to adalimumab. Three (18.8%) children did not receive prior immunosuppressive therapy. The average number of adalimumab injections given was 20.3 ± 12.0 at an interval of 2 weeks. The mean follow-up duration was 22.2 ± 16.6 months. Disease inactivity was achieved in 28 (96.6%) eyes at last visit ( P < 0.001). The best-corrected visual acuity (BCVA) improved from 0.48 ± 0.6 logMAR (logarithm of minimum of resolution) units at baseline to 0.20 ± 0.2 logMAR units at last visit ( P = 0.018). Disease remission was achieved in 23 (79.3%) eyes at the third month ( P = 0.001). Conclusion: Adalimumab is effective in the treatment of pediatric noninfectious uveitis by achieving disease inactivity, reducing the recurrence rate and improving BCVA. The drug is safe and well tolerated.
Immunopharmacotherapy of non-infectious uveitis: where do we stand?

Rupesh Agrawal,Cecilia Lee,Sumita Phatak,Carlos Pavesio

DOI: https://doi.org/10.1517/14712598.2014.963049

2014-09-22

Expert Opinion on Biological Therapy

Abstract:With ever-evolving concept of personalised medicine backed up with specific biomarkers for ocular inflammatory disease, there is a sudden surge of using biologics in non-infectious recalcitrant posterior uveitis. Have we understood these biologic agents enough to embark on this long enduring journey with the patient to optimise control of intraocular inflammation? On the other hand, there is still a strong inhibition of using these novel agents in management of uveitis even at tertiary referral centres. Immunopharmacotherapy of non-infectious uveitis poses a significant conundrum for both physicians and patients as it is like a two-edged sword effective to control inflammation but at the same time potentially toxic, suspected of causing long-term adverse effects. Systemic immunosuppressive therapy is used in a substantial number of most vision-threatening ocular inflammatory diseases. There is lack of randomised control trials establishing the safety of this therapy and our current practice pattern is based on retrospective studies and personal experience in using this treatment modality. This overview will highlight on the current dilemma faced by the clinicians in opting for steroid-sparing immunosuppressive therapy.

medicine, research & experimental,biotechnology & applied microbiology
Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review

Manuel Busto-Iglesias,Lorena Rodríguez-Martínez,Carmen Antía Rodríguez-Fernández,Jaime González-López,Miguel González-Barcia,Begoña de Domingo,Luis Rodríguez-Rodríguez,Anxo Fernández-Ferreiro,Cristina Mondelo-García

DOI: https://doi.org/10.3390/pharmaceutics15030766

IF: 6.525

2023-02-26

Pharmaceutics

Abstract:Biological drugs, especially those targeting anti-tumour necrosis factor α (TNFα) molecule, have revolutionized the treatment of patients with non-infectious uveitis (NIU), a sight-threatening condition characterized by ocular inflammation that can lead to severe vision threatening and blindness. Adalimumab (ADA) and infliximab (IFX), the most widely used anti-TNFα drugs, have led to greater clinical benefits, but a significant fraction of patients with NIU do not respond to these drugs. The therapeutic outcome is closely related to systemic drug levels, which are influenced by several factors such as immunogenicity, concomitant treatment with immunomodulators, and genetic factors. Therapeutic drug monitoring (TDM) of drug and anti-drug antibody (ADAbs) levels is emerging as a resource to optimise biologic therapy by personalising treatment to bring and maintain drug concentration within the therapeutic range, especially in those patients where a clinical response is less than expected. Furthermore, some studies have described different genetic polymorphisms that may act as predictors of response to treatment with anti-TNFα agents in immune-mediated diseases and could be useful in personalising biologic treatment selection. This review is a compilation of the published evidence in NIU and in other immune-mediated diseases that support the usefulness of TDM and pharmacogenetics as a tool to guide clinicians' treatment decisions leading to better clinical outcomes. In addition, findings from preclinical and clinical studies, assessing the safety and efficacy of intravitreal administration of anti-TNFα agents in NIU are discussed.

pharmacology & pharmacy

Personality traits, interpersonal problems and therapeutic alliance in early schizophrenia spectrum disorders.

Non-infectious Chronic Uveitis in Childhood: Assessment and Treatment in the Biological Era

Biological Therapy of Traditional Therapy-Resistant Adult-Onset Still’s Disease: an Evidence-Based Review

An Update on Treatment of Pediatric Chronic Non-infectious Uveitis

Religious Involvement and Health in Dialysis Patients in Saudi Arabia

Electrochemical genosensor assay using lyophilized gold nanoparticles/latex microsphere label for detection of Vibrio cholerae.

Isolated bilateral abducent nerve palsy in infectious mononucleosis.

A Summary of the Latest Data from a 5-Year Literature Review (2018–2023)

NOD-Like Receptor P3 Inflammasome Controls Protective Th1/Th17 Immunity against Pulmonary Paracoccidioidomycosis

Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond

Pediatric uveitis: A comprehensive review

The present status of canine parvovirosis.

New therapies in development for the management of non‐infectious uveitis: A review

To switch or to swap? Evidence from a meta-analysis for the best treatment approach in childhood chronic uveitis resistant to the I anti-TNF

Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry

Use of immunomodulators in non-infectious uveitis: lights and shadows

[Research Update of Anti-Tnf-α Biologic Agents in the Treatment of Uveitis].

Efficacy of adalimumab in noninfectious pediatric uveitis: Analysis of 29 eyes from a tertiary eye care center in India

Immunopharmacotherapy of non-infectious uveitis: where do we stand?

Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review